Effectiveness of Dual Biologic or Small Molecule Therapy for Achieving Endoscopic Remission in Refractory Inflammatory Bowel Disease

por Abdullah, Israa, AlMojil, Khaled, Shehab, Mohammad
Publicado 2022

Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel...

por Alrashed, Fatema, Abdullah, Israa, Alfadhli, Ahmad, Shehab, Mohammad
Publicado 2023

Gastroenterologists Adherence to Tumor Necrosis Factor Antagonist Combination Therapy in Inflammatory Bowel Disease

por Abdullah, Israa, Alhendi, Ghadeer, Alhadab, Anwar, Alasfour, Hajer, Shehab, Mohammad
Publicado 2021

Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis

por Alrashed, Fatema, Battat, Robert, Abdullah, Israa, Charabaty, Aline, Shehab, Mohammad
Publicado 2021

Relationship Between Patient Sex and Serum Tumor Necrosis Factor Antagonist Drug and Anti-drug Antibody Concentrations in Inflammatory Bowel Disease; A Nationwide Cohort Study

por Shehab, Mohammad, Alasfour, Hajer, Abdullah, Israa, Alhendi, Ghadeer, Alhadab, Anwar, Alfadhli, Ahmad, Ziyab, Ali H., Battat, Robert
Publicado 2021

Impact of tumor necrosis factor antagonist combination and anti-integrin therapies on body mass index in inflammatory bowel disease: A cross-sectional study

por Shehab, Mohammad, Alali, Ali, Al-Hindawi, Ahmed, Alsayegh, Abdulwahab, Aldallal, Usama, Abdullah, Israa, Albaghli, Abbas, Alrashed, Fatema, Alfadhli, Ahmad, Bessissow, Talat
Publicado 2023

Impact of BNT162b2 mRNA Vaccination on the Development of Short and Long-Term Vaccine-Related Adverse Events in Inflammatory Bowel Disease: A Multi-Center Prospective Study

por Shehab, Mohammad, Alrashed, Fatema, Abdullah, Israa, Alfadhli, Ahmad, Ali, Hamad, Abu-Farha, Mohamed, Channanath, Arshad Mohamed, Abubaker, Jehad Ahmed, Al-Mulla, Fahd
Publicado 2022